title: Blockade of phosphodiesterase Type 5 enhances rat neurohypophysial excitability and electrically evoked oxytocin release.
abstract: Phosphodiesterase type 5 (PDE5) acts specifically on cyclic guanosine monophosphate (cGMP) and terminates cGMP-mediated signalling. PDE5 has a well established role in vascular smooth muscle, where specific inhibitors of PDE5 such as sildenafil correct erectile dysfunction by augmenting cGMP-mediated vascular relaxation. However, the role of PDE5 outside of the vasculature has received little attention. The present study tested PDE5 inhibitors on the cGMP-mediated modulation of K(+) channels in the neurohypophysis (posterior pituitary). Photolysis of caged-cGMP enhanced current through Ca(2+)-activated K(+) channels, and this enhancement recovered in about 2 min. Sildenafil essentially eliminated this recovery, suggesting that the reversal of K(+) current enhancement depends on cGMP breakdown. Activation of nitric oxide synthase during trains of activity in pituitary nerve terminals enhances excitability. When trains of stimulation were applied at regular intervals, sildenafil enhanced the excitability of neurohypophysial nerve terminals and increased the action potential firing probability. T-1032, a compound with high specificity for PDE5 over PDE6, had a similar action. Voltage imaging in intact neurohypophysis with a voltage sensitive absorbance dye showed that T-1032 reduced the failure of propagating action potentials during trains of activity. This indicates that PDE5 activity limits action potential propagation in neurohypophysial axons. Immunoassay of oxytocin, a neuropeptide hormone secreted by the posterior pituitary, demonstrated that sildenafil increased electrically evoked release. Thus, PDE5 plays an important role in the regulation of neurohypophysial function, and blockade of this enzyme can enhance the use-dependent facilitation of neurohypophysial secretion.
authors: Department of Physiology, University of Wisconsin, Madison WI, USA.
authors: Zhenjie
authors: Z
authors: Zhang
authors: Vitaly
authors: V
authors: Klyachko
authors: Meyer B
authors: MB
authors: Jackson
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000378:metabolism*; D004558:Electric Stimulation; D066298:In Vitro Techniques; D008297:Male; D010121:Oxytocin / Q000378:metabolism*; D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines / Q000494:pharmacology; D010904:Pituitary Gland, Posterior / Q000201:enzymology / Q000378:metabolism*; D015221:Potassium Channels / Q000378:metabolism; D017729:Presynaptic Terminals / Q000378:metabolism*; D011687:Purines / Q000494:pharmacology; D051381:Rats; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000494:pharmacology
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D015221:Potassium Channels; D011687:Purines; D013450:Sulfones; D010121:Oxytocin; D000068677:Sildenafil Citrate; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5
references: J Am Pharm Assoc (2003). 2005 Jan-Feb;45(1):63-72; quiz 73-5
references: 15730119
references: Arch Gen Psychiatry. 2000 Nov;57(11):1012-30
references: 11074867
references: J Urol. 2003 Dec;170(6 Pt 1):2333-8
references: 14634409
references: J Physiol. 1986 Nov;380:521-39
references: 3612574
references: J Neurosci. 1991 Jan;11(1):85-95
references: 1986070
references: Exp Brain Res. 1988;72(3):535-42
references: 3234502
references: Int J Impot Res. 2003 Oct;15(5):369-72
references: 14562139
references: Urology. 2002 Sep;60(2 Suppl 2):4-11
references: 12414329
references: J Biol Chem. 2000 Sep 15;275(37):28810-5
references: 10833522
references: Ann N Y Acad Sci. 1992 Jun 12;652:1-492
references: 1352667
references: Nat Rev Drug Discov. 2002 Sep;1(9):674-82
references: 12209148
references: Eur J Obstet Gynecol Reprod Biol. 2003 Oct 10;110(2):201-6
references: 12969584
references: J Med Chem. 2001 Jun 21;44(13):2204-18
references: 11405657
references: J Neurosci. 2003 Dec 10;23(36):11352-62
references: 14672999
references: Adv Second Messenger Phosphoprotein Res. 1999;33:251-77
references: 10218122
references: Trends Neurosci. 2002 Oct;25(10):510-7
references: 12220879
references: J Physiol. 2006 Oct 15;576(Pt 2):427-43
references: 16873414
references: J Physiol. 1999 Oct 1;520 Pt 1:165-76
references: 10517809
references: Neuron. 2001 Sep 27;31(6):1015-25
references: 11580900
references: Fertil Steril. 2006 May;85(5):1496-501
references: 16579999
references: BJU Int. 2005 Aug;96(3):257-80
references: 16042713
references: J Physiol. 1995 Mar 15;483 ( Pt 3):597-611
references: 7776246
references: J Gen Physiol. 1996 Mar;107(3):353-68
references: 8868047
references: Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3199-204
references: 11867766
references: J Physiol. 1992 Dec;458:41-67
references: 1302271
references: Prog Neurobiol. 2005 May;76(1):1-21
references: 16043278
references: Neuroscience. 1982 Apr;7(4):773-808
references: 6124897
references: Nature. 1990 Oct 25;347(6295):768-70
references: 1700301
references: J Physiol Pharmacol. 2002 Dec;53(4 Pt 1):503-14
references: 12512688